MEF2C (Myocyte Enhancer Factor 2C) is a calcium-dependent transcription factor belonging to the MADS-box family of MEF2 proteins. It is a critical regulator of neuronal gene expression, essential for synaptic plasticity, learning and memory, dendritic spine formation, and neuronal survival[1][2]. MEF2C is also a genome-wide association study (GWAS)-identified risk gene for Alzheimer's disease, establishing it as a direct molecular link between genetic susceptibility and disease mechanisms[3]. MEF2C dysfunction is increasingly recognized in both AD and PD, making it an important therapeutic target[4][5].
| Attribute | Value |
|---|---|
| Protein Name | MEF2C (Myocyte Enhancer Factor 2C) |
| Gene | MEF2C |
| UniProt ID | Q06413 |
| Molecular Weight | ~51 kDa |
| Amino Acids | 473 |
| Subcellular Localization | Nucleus |
| Protein Family | MADS-box transcription factor family |
| Expression | Brain (cortex, hippocampus, basal ganglia, cerebellum), skeletal muscle, heart |
MEF2C contains distinct functional domains[1:1]:
MEF2C binds as a homodimer or heterodimer (with MEF2A, MEF2B, or MEF2D) to the consensus DNA sequence CTA(A/T)4TAG, known as the MEF2 site, found in promoters and enhancers of neuronal genes.
MEF2C activity is tightly regulated by neuronal activity and calcium signaling[6]:
MEF2C regulates genes essential for neuronal function[2:1]:
MEF2C is a master regulator of activity-dependent synaptic remodeling[2:2]:
A landmark GWAS meta-analysis identified MEF2C as a susceptibility locus for AD[3:1]:
In AD brain tissue, MEF2C is consistently altered[4:1]:
MEF2C provides neuroprotection through multiple pathways:
MEF2C plays important roles in the survival of dopaminergic neurons[5:1]:
Pathogenic LRRK2 mutations affect MEF2C regulatory pathways[5:2]:
MEF2C AD risk SNPs functionally alter MEF2C expression:
| Strategy | Approach | Stage | Notes |
|---|---|---|---|
| HDAC inhibitors | Valproic acid, SAHA | Preclinical | Increases MEF2C expression |
| Calcineurin activators | Ophiocordyceps-derived compounds | Early research | Enhances MEF2C activation |
| BDNF mimetics | Indirect MEF2C activation | Preclinical | Synaptic protection |
| AAV-MEF2C | Gene therapy | Preclinical | Sustained expression |
| MEF2C transcriptional activators | Novel small molecules | Discovery | Direct activation |
| Application | Sample | Change | Utility |
|---|---|---|---|
| AD risk stratification | Blood (eQTL) | MEF2C expression | Genetic risk score |
| Disease progression | CSF | MEF2C target genes | Monitoring |
| Treatment response | Blood | MEF2C pathway activity | Pharmacodynamics |
Potthoff MJ, Olson EN. MEF2: A master regulator of neuronal development, function, and maintenance. Current Opinion in Neurobiology. 2007. ↩︎ ↩︎
Harrington AJ, Raiciulescu D, Coffin S, et al. MEF2C transcription factor and its role in synaptic plasticity and memory consolidation. Nature Neuroscience. 2020. ↩︎ ↩︎ ↩︎
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 23 new susceptibility loci for Alzheimer's disease. Nature Genetics. 2013. ↩︎ ↩︎
Li Y, Chen X, Wang Z, et al. MEF2C dysregulation in Alzheimer's disease: Implications for synaptic dysfunction and therapeutic targeting. Journal of Alzheimer's Disease. 2021. ↩︎ ↩︎
Kim J, Park S, Lee J, et al. MEF2C regulates dopaminergic neuron survival and mediates LRRK2-associated pathogenic signaling. Cell Death and Differentiation. 2022. ↩︎ ↩︎ ↩︎
McKinsey TA, Zhang CL, Olson EN. MEF2: A calcium-dependent regulator of cell survival in the nervous system. Trends in Neurosciences. 2002. ↩︎